Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

OPDIVO 600 mg/5 ml solution for injection

Active Ingredient:
nivolumab
Company:  
Bristol Myers Squibb Pharmaceuticals limited See contact details
ATC code: 
L01FF01
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Opdivo (nivolumab) Patient Card

This Patient Card is a condition of the marketing authorisation for Opdivo (nivolumab) and contains important safety information that you need to be aware of. This Patient Card was last updated in April 2026 (minor editorial updates only).

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Bristol Myers Squibb Pharmaceuticals limited
Company image
Address
Bristol-Myers Squibb, ARC Uxbridge, Sanderson Road, New Denham, Denham, Buckinghamshire, UB8 1DH, UK
Telephone
+44 (0)1895 523 000
Medical Information e-mail
[email protected]
Medical Information Direct Line
+44 (0) 800 731 1736
Medical Information Website
https://www.bmsmedinfo.co.uk/